Cannabidiol: State of the art and new challenges for therapeutic applications

Pharmacology and Therapeutics

Volumn 175, Issue , 2017, Pages 133-150

  Pisanti, Simona ^a   Malfitano, Anna Maria ^a   Ciaglia, Elena ^a   Lamberti, Anna ^a   Ranieri, Roberta ^a   Cuomo, Gaia ^a   Abate, Mario ^a   Faggiana, Giorgio ^a   Proto, Maria Chiara ^b   Fiore, Donatella ^b   Laezza, Chiara ^c   Bifulco, Maurizio ^a,d  

^a UNIVERSITY OF SALERNO   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

^c CNR   (Italy)

^d NONE   (Italy)

Author keywords

Cancer; Cannabidiol; Cannabis; Endocannabinoid system; Neurological diseases

Indexed keywords

CANNABIDIOL; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR;

ALZHEIMER DISEASE; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BIOLOGICAL ACTIVITY; BRAIN CANCER; BRAIN FUNCTION; BREAST CANCER; CARDIOVASCULAR EFFECT; CARDIOVASCULAR FUNCTION; CHRONIC INFLAMMATION; CLINICAL PRACTICE; COLON CANCER; DRUG MECHANISM; EPILEPSY; HUMAN; HUNTINGTON CHOREA; IMMUNE SYSTEM; IMMUNOMODULATION; LUNG CANCER; METABOLISM; MULTIPLE SCLEROSIS; NERVOUS SYSTEM; NEUROLOGIC DISEASE; NEUROPROTECTION; PARKINSON DISEASE; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; SPASTICITY; TOXICOLOGY; ANIMAL;

ANIMALS; CANNABIDIOL; HUMANS; NERVOUS SYSTEM DISEASES;

EID: 85014006843     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2017.02.041     Document Type: Review

References (263)

1. Ali, R.M., Al Kury, L.T., Yang, K.H., Qureshi, A., Rajesh, M., Galadari, S., et al. Effects of cannabidiol on contractions and calcium signaling in rat ventricular myocytes. Cell Calcium 57 (2015), 290–299.
2. Ali, T.H., Pisanti, S., Ciaglia, E., Mortarini, R., Anichini, A., Garofalo, C.,.. Carbone, E., Enrichment of CD56(dim)KIR + CD57 + highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. Nature Communications, 5, 2014, 5639.
3. Almeida, V., Levin, R., Peres, F.F., Niigaki, S.T., Calzavara, M.B., Zuardi, A.W., et al. Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test. Progress in Neuropsychopharmacology and Biological Psychiatry 41 (2013), 30–35.
4. Andre, C.M., Hausman, J.F., Guerriero, G., Cannabis sativa: The plant of the thousand and one molecules. Frontiers in Plant Science 4 (2016), 7–19.
5. Appendino, G., Chianese, G., Taglialatela-Scafati, O., Cannabinoids: occurrence and medicinal chemistry. Current Medicinal Chemistry 18 (2011), 1085–1099.
6. Appendino, G., Gibbons, S., Giana, A., Pagani, A., Grassi, G., Stavri, M., et al. Antibacterial cannabinoids from Cannabis sativa: a structure-activity study. Journal of Natural Products 71 (2008), 1427–1430.
7. Armstrong, J.L., Hill, D.S., McKee, C.S., Hernandez-Tiedra, S., Lorente, M., Lopez-Valero, I., et al. Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death. Journal of Investigative Dermatology 135 (2015), 1629–1637.
8. Asbun, J., Villarreal, F.J., The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. Journal of the American College of Cardiology, 47, 2006.
9. Aviello, G., Romano, B., Borrelli, F., Capasso, R., Gallo, L., Piscitelli, F., et al. Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. Journal of Molecular Medicine 90 (2012), 925–934.
10. Bagher, A.M., Laprairie, R.B., Kelly, M.E., Denovan-Wright, E.M., Antagonism of dopamine receptor 2 long affects cannabinoid receptor 1 signaling in a cell culture model of striatal medium spiny projection neurons. Molecular Pharmacology 89 (2016), 652–666.
11. Bátkai, S., Pacher, P., Endocannabinoids and cardiac contractile function: pathophysiological implications. Pharmacological Research 60 (2009), 99–106.
12. + current. Journal of Biological Chemistry 278 (2003), 46188–46194.
13. Berenbaum, M.C., What is synergy?. Pharmacological Reviews 41 (1989), 93–141.
14. Bergamaschi, M.M., Queiroz, R.H., Chagas, M.H., de Oliveira, D.C., De Martinis, B.S., Kapczinski, F., et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 36 (2011), 1219–1226.
15. Bifulco, M., Di Marzo, V., Targeting the endocannabinoid system in cancer therapy: A call for further research. Nature Medicine 8 (2002), 547–550.
16. Bifulco, M., Pisanti, S., Medicinal use of cannabis in Europe: The fact that more countries legalize the medicinal use of cannabis should not become an argument for unfettered and uncontrolled use. EMBO Reports 16 (2015), 130–132.
17. Bisogno, T., Hanus, L., De Petrocellis, L., Tchilibon, S., Ponde, D.E., Brandi, I., et al. Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. British Journal of Pharmacology 134 (2001), 845–852.
18. Blázquez, C., Casanova, M.L., Planas, A., Gómez Del Pulgar, T., Villanueva, C., Fernández-Aceñero, M.J., et al. Inhibition of tumor angiogenesis by cannabinoids. FASEB Journal 17 (2003), 529–531.
19. Blázquez, C., González-Feria, L., Alvarez, L., Haro, A., Casanova, M.L., Guzmán, M., Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Research 64 (2004), 5617–5623.
20. Bondarenko, A.I., Endothelial atypical cannabinoid receptor: Do we have enough evidence?. British Journal of Pharmacology 171 (2014), 5573–5588.
21. Booz, G.W., Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radical Biology and Medicine 51 (2011), 1054–1061.
22. Borgelt, L.M., Franson, K.L., Nussbaum, A.M., Wang, G.S., The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy 33 (2013), 195–209.
23. Borrelli, F., Aviello, G., Romano, B., Orlando, P., Capasso, R., Maiello, F., et al. Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. Journal of Molecular Medicine 87 (2009), 1111–1121.
24. Boychuk, D.G., Goddard, G., Mauro, G., Orellana, M.F., The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: A systematic review. Journal of Oral & Facial Pain and Headache 29 (2015), 7–14.
25. Brodie, M.J., Barry, S.J., Bamagous, G.A., Norrie, J.D., Kwan, P., Patterns of treatment response in newly diagnosed epilepsy. Neurology 78 (2012), 1548–1554.
26. Brown, A.J., Novel cannabinoid receptors. British Journal of Pharmacology 52 (2007), 567–575.
27. Buccellato, E., Carretta, D., Utan, A., Cavina, C., Speroni, E., Grassi, G., et al. Acute and chronic cannabinoid extracts administration affects motor function in a CREAE model of multiplesclerosis. Journal of Ethnopharmacology 133 (2011), 1033–1038.
28. Campos, A.C., de Paula Soares, V., Carvalho, M.C., Ferreira, F.R., Vicente, M.A., Brandão, M.L., et al. Involvement of serotonin-mediated neurotransmission in the dorsal periaqueductal gray matter on cannabidiol chronic effects in panic-like responses in rats. Psychopharmacology 226 (2013), 13–24.
29. Campos, A.C., Fogaça, M.V., Sonego, A.B., Guimarães, F.S., Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacological Research 112 (2016), 119–127.
30. Candore, G., Bulati, M., Caruso, C., Castiglia, L., Colonna-Romano, G., Di Bona, D., et al. Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications. Rejuvenation Research 13 (2010), 301–313.
31. Carlini, E.A., Cunha, J.M., Hypnotic and antiepileptic effects of cannabidiol. Journal of Clinical Pharmacology 21 (1981), 417S–427S.
32. Carrier, E.J., Auchampach, J.A., Hillard, C.J., Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression. Proceedings of the National Academy of Sciences of the United States of America 103 (2006), 7895–7900.
33. Casanova, M.L., Blázquez, C., Martínez-Palacio, J., Villanueva, C., Fernández-Aceñero, M.J., Huffman, J.W., et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. Journal of Clinical Investigation 111 (2003), 43–50.
34. Chagas, M.H., Eckeli, A.L., Zuardi, A.W., Pena-Pereira, M.A., Sobreira-Neto, M.A., Sobreira, E.T., et al. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: A case series. Journal of Clinical Pharmacy and Therapeutics 39 (2014), 564–566.
35. Chagas, M.H., Zuardi, A.W., Tumas, V., Pena-Pereira, M.A., Sobreira, E.T., Bergamaschi, M.M., et al. Effects of cannabidiol in the treatment of patients with Parkinson's disease: An exploratory double-blind trial. Journal of Psychopharmacology 28 (2014), 1088–1098.
36. Cheng, D., Low, J.K., Logge, W., Garner, B., Karl, T., Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1 ∆ E9 mice. Psychopharmacology 231 (2014), 3009–3017.
37. Cheng, D., Spiro, A.S., Jenner, A.M., Garner, B., Karl, T., Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer's disease transgenic mice. Journal of Alzheimer's Disease 42 (2014), 1383–1396.
38. Childs, R.W., Carlsten, M., Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: The force awakens. Nature Reviews Drug Discovery 14 (2015), 487–498.
39. Cho, D.H., Jo, Y.K., Hwang, J.J., Lee, Y.M., Roh, S.A., Kim, J.C., Caspase-mediated cleavage of ATG6/Beclin-1 links apoptosis to autophagy in HeLa cells. Cancer Letters 274 (2009), 95–100.
40. Ciaglia, E., Pisanti, S., Picardi, P., Laezza, C., Sosa, S., Tubaro, A.,.. Bifulco, M., N6-isopentenyladenosine affects cytotoxic activity and cytokines production by IL-2 activated NK cells and exerts topical anti-inflammatory activity in mice. Pharmacological Research 89 (2014), 1–10.
41. Comelli, F., Bettoni, I., Colleoni, M., Giagnoni, G., Costa, B., Beneficial effects of a Cannabis sativa extract treatment on diabetes-induced neuropathy and oxidative stress. Phytotherapy Research 23 (2009), 1678–1684.
42. Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., et al. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacology Biochemistry and Behavior 40 (1991), 701–708.
43. Costa, B., Giagnoni, G., Franke, C., Trovato, A.E., Colleoni, M., Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. British Journal of Pharmacology 143 (2004), 247–250.
44. Costa, B., Trovato, A.E., Comelli, F., Giagnoni, G., Colleoni, M., The non-psychoactive Cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. European Journal of Pharmacology 556 (2007), 75–83.
45. Crippa, J.A., Derenusson, G.N., Ferrari, T.B., Wichert-Ana, L., Duran, F.L., Martin-Santos, R., et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report. Journal of Psychopharmacology 25 (2011), 121–130.
46. Crippa, J.A., Hallak, J.E., Abílio, V.C., de Lacerda, A.L., Zuardi, A.W., Cannabidiol and sodium nitroprusside: Two novel neuromodulatory pharmacological interventions to treat and prevent psychosis. CNS & Neurological Disorders Drug Targets 14 (2015), 970–978.
47. Crippa, J.A., Zuardi, A.W., Hallak, J.E., Therapeutical use of the cannabinoids in psychiatry. Revista Brasileira de Psiquiatria 32 (2010), S56–S66.
48. da Silva, V.K., de Freitas, B.S., da Silva Dornelles, A., Nery, L.R., Falavigna, L., Ferreira, R.D., Bogo, M.R., Hallak, J.E., Zuardi, A.W., Crippa, J.A., Schröder, N., Cannabidiol normalizes caspase 3, synaptophysin, and mitochondrial fission protein DNM1L expression levels in rats with brain iron overload: implications for neuroprotection. Molecular Neurobiology 49 (2014), 222–233.
49. De Filippis, D., Esposito, G., Cirillo, C., Cipriano, M., De Winter, B.Y., Scuderi, C., et al. Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. PLoS One, 6(12), 2011, e28159.
50. De Petrocellis, L., Ligresti, A., Schiano Moriello, A., Iappelli, M., Verde, R., Stott, C.G., et al. Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: Pro-apoptotic effects and underlying mechanisms. British Journal of Pharmacology 168 (2013), 79–102.
51. Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., et al. Cannabidiol in patients with treatment-resistant epilepsy: An open-label interventional trial. Lancet Neurology 15 (2016), 270–278.
52. Dirikoc, S., Priola, S.A., Marella, M., Zsürger, N., Chabry, J., Nonpsychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity. Journal of Neuroscience 27 (2007), 9537–9544.
53. Durst, R., Danenberg, H., Gallily, R., Mechoulam, R., Meir, K., Grad, E., et al. Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. American Journal of Physiology Heart and Circulatory Physiology 293 (2007), 3602–3607.
54. El-Alfy, A.T., Ivey, K., Robinson, K., Ahmed, S., Radwan, M., Slade, D., et al. Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacology Biochemistry and Behavior 95 (2010), 434–442.
55. Elbaz, M., Ahirwar, D., Xiaoli, Z., Zhou, X., Lustberg, M., Nasser, M.W.,.. Ganju, R.K., TRPV2 is a novel biomarker and therapeutic target in triple negative breast cancer. Oncotarget, 2016, May 27, 10.18632/oncotarget.9663.
56. Elbaz, M., Nasser, M.W., Ravi, J., Wani, N.A., Ahirwar, D.K., Zhao, H., et al. Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: Novel anti-tumor mechanisms of cannabidiol in breast cancer. Molecular Oncology 9 (2015), 906–919.
57. El-Remessy, A.B., Al-Shabrawey, M., Khalifa, Y., Tsai, N.T., Caldwell, R.B., Liou, G.I., Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. American Journal of Pathology 168 (2006), 235–244.
58. Engel, J., Concepts of epilepsy. Epilepsia 36 (1995), S23–S29.
59. Engel, J., Starkman, S., Overview of seizures. Emergency Medicine Clinics of North America 12 (1994), 895–923.
60. Esposito, G., De Filippis, D., Carnuccio, R., Izzo, A.A., Iuvone, T., The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells. Journal of Molecular Medicine 84 (2006), 253–258.
61. Esposito, G., De Filippis, D., Maiuri, M.C., De Stefano, D., Carnuccio, R., Iuvone, T., Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement. Neuroscience Letters 399 (2006), 91–95.
62. Esposito, G., Scuderi, C., Savani, C., Steardo, L. Jr., De Filippis, D., Cottone, P., et al. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. British Journal of Pharmacology 151 (2007), 1272–1279.
63. 2 + entry in human pulmonary artery endothelial cells. American Journal of Physiology 285 (2003), 1233–1245.
64. Fernández-Ruiz, J., Sagredo, O., Pazos, M.R., García, C., Pertwee, R., Mechoulam, R., et al. Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid?. British Journal of Clinical Pharmacology, 75, 2013.
65. Flygare, J., Sander, B., The endocannabinoid system in cancer-potential therapeutic target?. Seminars in Cancer Biology 18 (2008), 176–189.
66. Fouad, A.A., Albuali, W.H., Al-Mulhim, A.S., Jresat, I., Cardioprotective effect of cannabidiol in rats exposed to doxorubicin toxicity. Environmental Toxicology and Pharmacology 36 (2013), 347–357.
67. Friedman, D., Devinsky, O., Cannabinoids in the treatment of epilepsy. New England Journal of Medicine 373 (2015), 1048–1058.
68. Gaoni, Y., Mechoulam, R., Isolation, structure, and partial synthesis of an active constituent of hashish. Journal of the American Chemical Society 86 (1964), 1646–1647.
69. Gaoni, Y., Mechoulam, R., Cannabichromene, a new active principle in hashish. Chemical Communications, 1966, 20–21.
70. García-Arencibia, M., González, S., de Lago, E., Ramos, J.A., Mechoulam, R., Fernández-Ruiz, J., Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: Importance of antioxidant and cannabinoid receptor-independent properties. Brain Research 1134 (2007), 162–170.
71. Gauson, L.A., Stevenson, L.A., Thomas, A., Cannabigerol behaves as a partial agonist at both CB1 and CB2 receptors. 17th Annual Symposium on the Cannabinoids, 2007, International Cannabinoid Research Society, Saint-Sauveur, Quebec, Canada, 206.
72. Giacoppo, S., Soundara Rajan, T., Galuppo, M., Pollastro, F., Grassi, G., Bramanti, P., et al. Purified cannabidiol, the main non-psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosis. European Review for Medical and Pharmacological Sciences 19 (2015), 4906–4919.
73. Gill, E.W., Paton, W.D., Pertwee, R.G., Preliminary experiments on the chemistry and pharmacology of cannabis. Nature 228 (1970), 134–136.
74. Gloss, D., Vickrey, B., Cannabinoids for epilepsy. Cochrane Database of Systematic Reviews, 3, 2014, CD009270.
75. Gomes, F.V., Llorente, R., Del Bel, E.A., Viveros, M.P., López-Gallardo, M., Guimarães, F.S., Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol. Schizophrenia Research 164 (2015), 155–163.
76. Grotenhermen, F., Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical Pharmacokinetics 42 (2003), 327–360.
77. Guertin, D.A., Sabatini, D.M., Defining the role of mTOR in cancer. Cancer Cell 12 (2007), 9–22.
78. Guindon, J., Hohmann, A.G., The endocannabinoid system and cancer: Therapeutic implication. British Journal of Pharmacology 163 (2011), 1447–1463.
79. Guzmán, M., Cannabinoids: Potential anticancer agents. Nature Reviews Cancer 3 (2003), 745–755.
80. Hampson, A.J., Grimaldi, M., Axelrod, J., Wink, D., Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proceedings of the National Academy of Sciences of the United States of America 95 (1998), 8268–8273.
81. Harvey, D.J., Mechoulam, R., Metabolites of cannabidiol identified in human urine. Xenobiotica 20 (1990), 303–320.
82. Haustein, M., Ramer, R., Linnebacher, M., Manda, K., Hinz, B., Cannabinoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1. Biochemical Pharmacology 92 (2014), 312–325.
83. Hayakawa, K., Irie, K., Sano, K., Watanabe, T., Higuchi, S., Enoki, M., et al. Therapeutic time window of cannabidiol treatment on delayed ischemic damage via high-mobility group box1-inhibiting mechanism. Biological and Pharmaceutical Bulletin 32 (2009), 1538–1544.
84. Hayakawa, K., Mishima, K., Nozako, M., Hazekawa, M., Irie, K., Fujioka, M., et al. Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism. Journal of Neurochemistry 102 (2007), 1488–1496.
85. Hegde, V.L., Nagarkatti, P.S., Nagarkatti, M., Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol. PLoS One, 6(4), 2011, e18281.
86. Hegde, V.L., Singh, U.P., Nagarkatti, P.S., Nagarkatti, M., Critical role of mast cells and peroxisome proliferator-activated receptor γ in the induction of Myeloid-derived suppressor cells by marijuana cannabidiol in vivo. Journal of Immunology 194 (2015), 5211–5222.
87. Hernàn Pérez de la Ossa, D., Ligresti, A., Gil-Alegre, M.E., Aberturas, M.R., Molpeceres, J., Di Marzo, V., et al. Poly-epsilon-caprolactone microspheres as a drug delivery system for cannabinoid administration: Development, characterization and in vitro evaluation of their antitumoral efficacy. Journal of Controlled Release 161 (2012), 927–932.
88. Hernàn Pérez de la Ossa, D., Lorente, M., Gil-Alegre, M.E., Torres, S., Garcìa-Taboada, E., del Rosario Aberturas, M., et al. Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme. PLoS One, 8(1), 2013, e54795.
89. Heurtaux, T., Michelucci, A., Losciuto, S., Gallotti, C., Felten, P., Dorban, G., et al. Microglial activation depends on beta-amyloid conformation: Role of the formylpeptide receptor 2. Journal of Neurochemistry 114 (2010), 576–586.
90. Hind, W.H., England, T.J., O'Sullivan, S.E., Cannabidiol protects an in vitro model of the blood-brain barrier from oxygen-glucose deprivation via PPARγ and 5-HT1A receptors. British Journal of Pharmacology 173 (2016), 815–825.
91. Hirsch, L.J., Finding the lesser of two evils: Treating refractory status epilepticus. Epilepsy Currents 15 (2015), 313–316.
92. Ho, W.S., Hiley, C.R., Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery. British Journal of Pharmacology 138 (2003), 1320–1332.
93. Holland, M.L., Lau, D.T., Allen, J.D., Arnold, J.C., The multidrug transporter ABCG2(BCRP) is inhibited by plant-derived cannabinoids. British Journal of Pharmacology 152 (2007), 815–824.
94. Hsiao, Y.T., Yi, P.L., Li, C.L., Chang, F.C., Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rats. Neuropharmacology 62 (2012), 373–384.
95. Hwang, J., Kleinhenz, D.J., Lassegue, B., Griendling, K.K., Dikalov, S., Hart, C.M., Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production. American Journal of Physiology. Cell Physiology 288 (2005), 899–905.
96. Ignatowska-Jankowska, B., Jankowski, M., Glac, W., Swiergel, A.H., Cannabidiol-induced lymphopenia does not involve NKT and NK cells. Journal of Physiology and Pharmacology 60 (2009), 99–103.
97. Iseger, T.A., Bossong, M.G., A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophrenia Research 162 (2015), 153–161.
98. Iuvone, T., Esposito, G., De Filippis, D., Scuderi, C., Steardo, L., Cannabidiol: A promising drug for neurodegenerative disorders?. CNS Neuroscience & Therapeutics 15 (2009), 65–75.
99. Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., Izzo, A.A., Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, onbeta-amyloid-induced toxicity in PC12 cells. Journal of Neurochemistry 89 (2004), 134–141.
100. Izzo, A.A., Camilleri, M., Cannabinoids in intestinal inflammation and cancer. Pharmacological Research 60 (2009), 117–125.
101. Johnson, J.R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E.D., Potts, R., Fallon, M.T., Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management 39 (2010), 167–179.
102. Jones, N.A., Hill, A.J., Smith, I., Bevan, S.A., Williams, C.M., Whalley, B.J., et al. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. Journal of Pharmacology and Experimental Therapeutics 332 (2010), 569–577.
103. Juknat, A., Pietr, M., Kozela, E., Rimmerman, N., Levy, R., Coppola, G., et al. Differential transcriptional profiles mediated by exposure to the cannabinoids cannabidiol and Δ9-tetrahydrocannabinol in BV-2 microglial cells. British Journal of Pharmacology 165 (2012), 2512–2528.
104. Kargl, J., Andersen, L., Hasenöhrl, C., Feuersinger, D., Stančić, A., Fauland, A., et al. GPR55 promotes migration and adhesion of colon cancer cells indicating a role in metastasis. British Journal of Pharmacology 173 (2016), 142–154.
105. Karmaus, P.W., Wagner, J.G., Harkema, J.R., Kaminski, N.E., Kaplan, B.L., Cannabidiol (CBD) enhances lipopolysaccharide (LPS)-induced pulmonary inflammation in C57BL/6 mice. Journal of Immunotoxicology 10 (2013), 321–328.
106. Kathmann, M., Flau, K., Redmer, A., Trankle, C., Schlicker, E., Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn-Schmiedebergs Archives of Pharmacology 372 (2006), 354–361.
107. Katona, I., Cannabis and Endocannabinoid Signaling in Epilepsy. Handbook of Experimental Pharmacology 231 (2015), 285–316.
108. Kianirad, Y., Simuni, T., Novel approaches to optimization of levodopa therapy for Parkinson's disease. Current Neurology and Neuroscience Reports, 16, 2016, 34.
109. Kleihues, P., Louis, D.N., Scheithauer, B.W., Rorke, L.B., Reifenberger, G., Burger, P.C., et al. The WHO classification of tumors of the nervous system. Journal of Neuropathology and Experimental Neurology 61 (2002), 215–225.
110. Kogan, N.M., Rabinowitz, R., Levi, P., Gibson, D., Sandor, P., Schlesinger, M., et al. Synthesis and antitumor activity of quinonoid derivatives of cannabinoids. Journal of Medicinal Chemistry 47 (2004), 3800–3806.
111. Kogan, N.M., Schlesinger, M., Priel, E., Rabinowitz, R., Berenshtein, E., Chevion, M., et al. HU-331, a novel cannabinoid-based anticancer topoisomerase IIinhibitor. Molecular Cancer Therapeutics 6 (2007), 173–183.
112. Kozela, E., Juknat, A., Gao, F., Kaushansky, N., Coppola, G., Vogel, Z., Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells. Journal of Neuroinflammation, 13, 2016, 136.
113. Kozela, E., Juknat, A., Kaushansky, N., Ben-Nun, A., Coppola, G., Vogel, Z., Cannabidiol, a non-psychoactive cannabinoid, leads to EGR2-dependent anergy in activated encephalitogenic Tcells. Journal of Neuroinflammation, 12, 2015, 52.
114. Kozela, E., Juknat, A., Kaushansky, N., Rimmerman, N., Ben-Nun, A., Vogel, Z., Cannabinoids decrease the th17 inflammatory autoimmune phenotype. Journal of Neuroimmune Pharmacology 8 (2013), 1265–1276.
115. Kozela, E., Lev, N., Kaushansky, N., Eilam, R., Rimmerman, N., Levy, R., et al. Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiplesclerosis-like disease in C57BL/6 mice. British Journal of Pharmacology 163 (2011), 1507–1519.
116. Kozela, E., Pietr, M., Juknat, A., Rimmerman, N., Levy, R., Vogel, Z., Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells. Journal of Biological Chemistry 285 (2010), 1616–1626.
117. Kwan, P., Brodie, M.J., Early identification of refractory epilepsy. New England Journal of Medicine 342 (2000), 314–319.
118. Laprairie, R.B., Bagher, A.M., Kelly, M.E., Denovan-Wright, E.M., Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. British Journal of Pharmacology 172 (2015), 4790–4805.
119. Lastres-Becker, I., Molina-Holgado, F., Ramos, J.A., Mechoulam, R., Fernández-Ruiz, J., Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiology of Disease 19 (2005), 96–107.
120. Lee, C.Y., Landreth, G.E., The role of microglia in amyloid clearance from the AD brain. Journal of Neural Transmission 117 (2010), 949–960.
121. Lee, C.Y., Wey, S.P., Liao, M.H., Hsu, W.L., Wu, H.Y., Jan, T.R., A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells. International Immunopharmacology 8 (2008), 732–740.
122. Lemos, J.I., Resstel, L.B., Guimarães, F.S., Involvement of the prelimbic prefrontal cortex on cannabidiol-induced attenuation of contextual conditioned fear in rats. Behavioural Brain Research 207 (2010), 105–111.
123. Ligresti, A., Moriello, A.S., Starowicz, K., Matias, I., Pisanti, S., De Petrocellis, L., et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. Journal of Pharmacology and Experimental Therapeutics 318 (2006), 1375–1387.
124. Liou, G.I., Auchampach, J.A., Hillard, C.J., Zhu, G., Yousufzai, B., Mian, S., et al. Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A2A adenosine receptor. Investigative Ophthalmology & Visual Science 49 (2008), 5526–5531.
125. Liu, D.Z., Hu, C.M., Huang, C.H., Wey, S.P., Jan, T.R., Cannabidiol attenuates delayed-type hypersensitivity reactions via suppressing T-cell and macrophage reactivity. Acta Pharmacologica Sinica 31 (2010), 1611–1617.
126. Lunn, C.A., Reich, E.P., Bober, L., Targeting the CB2 receptor for immune modulation. Expert Opinion on Therapeutic Targets 10 (2006), 653–663.
127. MacIntyre, J., Dong, A., Straiker, A., Zhu, J., Howlett, S.E., Bagher, A., et al. Cannabinoid and lipid-mediated vasorelaxation in retinal microvasculature. European Journal of Pharmacology 735 (2014), 105–114.
128. MacLennan, S.J., Reynen, P.H., Kwan, J., Bonhaus, D.W., Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. British Journal of Pharmacology 124 (1998), 619–622.
129. Magen, I., Avraham, Y., Ackerman, Z., Vorobiev, L., Mechoulam, R., Berry, E.M., Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. Journal of Hepatology 51 (2009), 528–534.
130. Malfait, A.M., Gallily, R., Sumariwalla, P.F., Malik, A.S., Andreakos, E., Mechoulam, R., et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proceedings of the National Academy of Sciences of the United States of America 97 (2000), 9561–9566.
131. Malfitano, A.M., Ciaglia, E., Gangemi, G., Gazzerro, P., Laezza, C., Bifulco, M., Update on the endocannabinoid system as an anticancer target. Expert Opinion on Therapeutic Targets 15 (2011), 297–308.
132. Marcu, J.P., Christian, R.T., Lau, D., Zielinski, A.J., Horowitz, M.P., Lee, J., et al. Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Molecular Cancer Therapeutics 9 (2010), 180–189.
133. 1A receptors and stressful experiences. Behavioural Brain Research 286 (2015), 49–56.
134. Martín-Moreno, A.M., Reigada, D., Ramírez, B.G., Mechoulam, R., Innamorato, N., Cuadrado, A., et al. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: Relevance to Alzheimer's disease. Molecular Pharmacology 79 (2011), 964–973.
135. Massi, P., Vaccani, A., Ceruti, S., Colombo, A., Abbracchio, M.P., Parolaro, D., Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. Journal of Pharmacology and Experimental Therapeutics 308 (2004), 838–845.
136. Massi, P., Valenti, M., Vaccani, A., Gasperi, V., Perletti, G., Marras, E., et al. 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psycoactivecannabidiol. Journal of Neurochemistry 104 (2008), 1091–1100.
137. McAllister, S.D., Chan, C., Taft, R.J., Luu, T., Abood, M.E., Moore, D.H., et al. Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells. Journal of Neuro-Oncology 74 (2005), 31–40.
138. McAllister, S.D., Murase, R., Christian, R.T., Lau, D., Zielinski, A.J., Allison, J., et al. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Research and Treatment 129 (2011), 37–47.
139. McHugh, D., McMaster, R.S., Pertwee, R.G., Roy, S., Mahadevan, A., Razdan, R.K., et al. Novel compounds that interact with both leukotriene B4 receptors and vanilloid TRPV1 receptors. Journal of Pharmacology and Experimental Therapeutics 316 (2006), 955–965.
140. McKallip, R.J., Jia, W., Schlomer, J., Warren, J.W., Nagarkatti, P.S., Nagarkatti, M., Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression. Molecular Pharmacology 70 (2006), 897–908.
141. McKallip, R.J., Lombard, C., Martin, B.R., Nagarkatti, M., Nagarkatti, P.S., Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. Journal of Pharmacology and Experimental Therapeutics 302 (2002), 451–465.
142. Mecha, M., Feliú, A., Iñigo, P.M., Mestre, L., Carrillo-Salinas, F.J., Guaza, C., Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors. Neurobiology of Disease 59 (2013), 141–150.
143. Mecha, M., Torrao, A.S., Mestre, L., Carrillo-Salinas, F.J., Mechoulam, R., Guaza, C., Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress. Cell Death & Disease, 28(3), 2012, e331.
144. Mechoulam, R., Shvo, Y., The structure of cannabidiol, Vol. 19, 1963, Pergamon Prem Ltd., 2073–2078.
145. de Mello Schier, A.R., de Oliveira Ribeiro, N.P., Coutinho, D.S., Machado, S., Arias-Carrión, O., Crippa, J.A., et al. Antidepressant-like and anxiolytic-like effects of cannabidiol: A chemical compound of Cannabis sativa. CNS & Neurological Disorders Drug Targets 13 (2014), 953–960.
146. Mishima, K., Hayakawa, K., Abe, K., Ikeda, T., Egashira, N., Iwasaki, K., et al. Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism. Stroke 36 (2005), 1077–1082.
147. Montecucco, F., Di Marzo, V., At the heart of the matter: The endocannabinoid system in cardiovascular function and dysfunction. Trends in Pharmacological Sciences 33 (2012), 331–340.
148. Moreira, F.A., Aguiar, D.C., Guimarães, F.S., Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Progress in Neuro-Psychopharmacology & Biological Psychiatry 30 (2006), 1466–1471.
149. Munson, A.E., Harris, L.S., Friedman, M.A., Dewey, W.L., Carchman, R.A., Antineoplastic activity of cannabinoids. Journal of the National Cancer Institute 55 (1975), 597–602.
150. Murillo-Rodríguez, E., Millán-Aldaco, D., Palomero-Rivero, M., Mechoulam, R., Drucker-Colín, R., Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats. FEBS Letters 580 (2006), 4337–4345.
151. Murnion, B., Medicinal cannabis. Australian Prescriber 38 (2015), 212–215.
152. Nabissi, M., Morelli, M.B., Amantini, C., Liberati, S., Santoni, M., Ricci-Vitiani, L., et al. Cannabidiol stimulates Aml-1a-dependent glial differentiation and inhibits glioma stem-like cells proliferation by inducing autophagy in a TRPV2-dependent manner. International Journal of Cancer 137 (2015), 1855–1869.
153. Naftali, T., Lev, L.B., Yablecovitch, D., Half, E., Konikoff, F.M., Treatment of Crohn's disease with cannabis: An observational study. Israel Medical Association Journal 13 (2011), 455–458.
154. Nahas, G.G., Morishima, A., Desoize, B., Effects of cannabinoids on macromolecular synthesis and replication of cultured lymphocytes. Federation Proceedings 36 (1977), 1748–1752.
155. Ngugi, A.K., Kariuki, S.M., Bottomley, C., Kleinschmidt, I., Sander, J.W., Newton, C.R., Incidence of epilepsy: A systematic review and meta-analysis. Neurology 77 (2011), 1005–1012.
156. Nicholson, A.N., Turner, C., Stone, B.M., Robson, P.J., Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. Journal of Clinical Psychopharmacology 24 (2004), 305–313.
157. Noseworthy, J.H., Lucchinetti, C., Rodriguez, M., Weinshenker, B.G., Multiple sclerosis. New England Journal of Medicine 343 (2000), 938–952.
158. Offertáler, L., Mo, F.M., Bátkai, S., Liu, J., Begg, M., Razdan, R.K., et al. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Molecular Pharmacology 63 (2003), 699–705.
159. O'Sullivan, S.E., Kendall, D.A., Randall, M.D., Further characterization of the time-dependent vascular effects of delta9-tetrahydrocannabinol. Journal of Pharmacology and Experimental Therapeutics 317 (2006), 428–438.
160. O'Sullivan, S.E., Sun, Y., Bennett, A.J., Randall, M.D., Kendall, D.A., Time-dependent vascular actions of cannabidiol in the rat aorta. European Journal of Pharmacology 612 (2009), 61–68.
161. O'Sullivan, S.E., Tarling, E.J., Bennett, A.J., Kendall, D.A., Randall, M.D., Novel time-dependent vascular actions of Delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma. Biochemical and Biophysical Research Communications 337 (2005), 824–831.
162. Pacher, P.A., Endocannabinoids, cannabinoid receptors and inflammatory stress: An interview with Dr. Pál [corrected] Pacher. Interviewed by Helene F. Rosenberg. Journal of Leukocyte Biology, 82, 2007, 139.
163. Pan, H., Mukhopadhyay, P., Rajesh, M., Patel, V., Mukhopadhyay, B., Gao, B., et al. Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. Journal of Pharmacology and Experimental Therapeutics 328 (2009), 708–714.
164. Parker, L.A., Mechoulam, R., Schlievert, C., Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport 13 (2002), 567–570.
165. Parmar, N., Ho, W.S., N-arachidonoyl glycine, an endogenous lipid that acts as a vasorelaxant via nitric oxide and large conductance calcium-activated potassium channels. British Journal of Pharmacology 160 (2010), 594–603.
166. Parolaro, D., Massi, P., Cannabinoids as potential new therapy for the treatment of gliomas. Expert Review of Neurotherapeutics 8 (2008), 37–49.
167. Parolaro, D., Massi, P., Rubino, T., Monti, E., Endocannabinoids in the immune system and cancer. Prostaglandins, Leukotrienes and Essential Fatty Acids 66 (2002), 319–332.
168. Pazos, M.R., Cinquina, V., Gómez, A., Layunta, R., Santos, M., Fernández-Ruiz, J., et al. Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function. Neuropharmacology 63 (2012), 776–783.
169. Pazos, M.R., Mohammed, N., Lafuente, H., Santos, M., Martínez-Pinilla, E., Moreno, E., et al. Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: Role of 5HT(1A) and CB2 receptors. Neuropharmacology 71 (2013), 282–291.
170. Pertwee, R.G., Pharmacology of cannabinoid receptor ligands. Current Medicinal Chemistry 6 (1999), 635–664.
171. Pertwee, R.G., Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sciences 76 (2005), 1307–1324.
172. Pertwee, R.G., The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. British Journal of Pharmacology 153 (2008), 199–215.
173. Pertwee, R.G., Ross, R.A., Cannabinoid receptors and their ligands. Prostaglandins, Leukotrienes and Essential Fatty Acids 66 (2002), 101–121.
174. Pertwee, R.G., Ross, R.A., Craib, S.J., Thomas, A., (−)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. European Journal of Pharmacology 456 (2002), 99–106.
175. Pertwee, R.G., Thomas, A., Stevenson, L.A., Ross, R.A., Varvel, S.A., Lichtman, A.H., et al. The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo. British Journal of Pharmacology 76 (2007), 1307–1324.
176. Perucca, P., Gilliam, F.G., Adverse effects of antiepileptic drugs. Lancet Neurology 11 (2012), 792–802.
177. Petitet, F., Jeantaud, B., Reibaud, M., Imperato, A., Dubroeucq, M.C., Complex pharmacology of natural cannabinoids: Evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sciences 63 (1998), 1–6.
178. Petzke, F., Enax-Krumova, E.K., Häuser, W., Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: A systematic review of randomized controlled studies. Der Schmerz 30 (2016), 62–88.
179. Pisanti, S., Bifulco, M., Modern history of medical cannabis: From widespread use to prohibitionism and back. Trends in Pharmacological Sciences, 2017, Jan 14, 10.1016/j.tips.2016.12.002 (pii:S0165-6147(16)30184-5).
180. Pisanti, S., Borselli, C., Oliviero, O., Laezza, C., Gazzerro, P., Bifulco, M., Antiangiogenic activity of the endocannabinoid anandamide: Correlation to its tumor-suppressor efficacy. Journal of Cellular Physiology 211 (2007), 495–503.
181. Pisanti, S., Malfitano, A.M., Grimaldi, C., Santoro, A., Gazzerro, P., Laezza, C., Bifulco, M., Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents. Best Practice & Research. Clinical Endocrinology & Metabolism 23 (2009), 117–131.
182. Pisanti, S., Picardi, P., D'Alessandro, A., Laezza, C., Bifulco, M., The endocannabinoid signaling system in cancer. Trends in Pharmacological Sciences 34 (2013), 273–282.
183. Pisanti, S., Picardi, P., Prota, L., Proto, M.C., Laezza, C., McGuire, P.G., et al. Genetic and pharmacologic inactivation of cannabinoid CB1 receptor inhibits angiogenesis. Blood 117 (2011), 5541–5550.
184. Portella, G., Laezza, C., Laccetti, P., De Petrocellis, L., Di Marzo, V., Bifulco, M., Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: Actions on signals involved in angiogenesis and metastasis. FASEB Journal 17 (2003), 1771–1773.
185. Pryce, G., Riddall, D.R., Selwood, D.L., Giovannoni, G., Baker, D., Neuroprotection in experimental autoimmune encephalomyelitis and progressive multiple sclerosis by cannabis-based cannabinoids. Journal of Neuroimmune Pharmacology 10 (2014), 281–292.
186. Rajesh, M., Mukhopadhyay, P., Bátkai, S., Haskó, G., Liaudet, L., Drel, V.R., et al. Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. American Journal of Physiology - Heart and Circulatory Physiology 293 (2007), 610–619.
187. Rajesh, M., Mukhopadhyay, P., Bátkai, S., Patel, V., Saito, K., Matsumoto, S., et al. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. Journal of the American College of Cardiology 56 (2010), 2115–2125.
188. Ramer, R., Bublitz, K., Freimuth, N., Merkord, J., Rohde, H., Haustein, M., et al. Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB Journal 26 (2012), 1535–1548.
189. Ramer, R., Fischer, S., Haustein, M., Manda, K., Hinz, B., Cannabinoids inhibit angiogenic capacities of endothelial cells via release of tissue inhibitor of matrix metalloproteinases-1 from lung cancer cells. Biochemical Pharmacology 91 (2014), 202–216.
190. Ramer, R., Heinemann, K., Merkord, J., Rohde, H., Salamon, A., Linnebacher, M., et al. COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells. Molecular Cancer Therapeutics 12 (2013), 69–82.
191. Ramer, R., Merkord, J., Rohde, H., Hinz, B., Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. Biochemical Pharmacology 79 (2010), 955–966.
192. Ramer, R., Rohde, A., Merkord, J., Rohde, H., Hinz, B., Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells. Pharmaceutical Research 27 (2010), 2162–2174.
193. Randall, M.D., Harris, D., Kendall, D.A., Ralevic, V., Cardiovascular effects of cannabinoids. Pharmacology & Therapeutics 95 (2002), 191–202.
194. Ribeiro, A., Almeida, V.I., Costola-de-Souza, C., Ferraz-de-Paula, V., Pinheiro, M.L., Vitoretti, L.B., et al. Cannabidiol improves lung function and inflammation in mice submitted to LPS-induced acute lung injury. Immunopharmacology and Immunotoxicology 37 (2015), 35–41.
195. Ribeiro, A., Ferraz-de-Paula, V., Pinheiro, M.L., Vitoretti, L.B., Mariano-Souza, D.P., Quinteiro-Filho, W.M., et al. Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: Role for the adenosine A(2A) receptor. European Journal of Pharmacology 678 (2012), 78–85.
196. Rocha, F.C., Dos Santos Júnior, J.G., Stefano, S.C., da Silveira, D.X., Systematic review of the literature on clinical and experimental trials on the antitumor effects ofcannabinoids in gliomas. Journal of Neuro-Oncology 116 (2014), 11–24.
197. Rock, E.M., Limebeer, C.L., Mechoulam, R., Piomelli, D., Parker, L.A., The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacology 196 (2008), 389–395.
198. Rosenberg, E.C., Tsien, R.W., Whalley, B.J., Devinsky, O., Cannabinoids and epilepsy. Neurotherapeutics 12 (2015), 747–768.
199. Rosenkrantz, H., Fleischman, R.W., Grant, R.J., Toxicity of short-term administration of cannabinoids to rhesus monkeys. Toxicology and Applied Pharmacology 58 (1981), 118–131.
200. Rosenkrantz, H., Hayden, D.W., Acute and subacute inhalation toxicity of Turkish marihuana, cannabichromene, and cannabidiol in rats. Toxicology and Applied Pharmacology 48 (1979), 375–386.
201. Russo, E.B., Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology 163 (2011), 1344–1364.
202. Russo, E.B., Burnett, A., Hall, B., Parker, K.K., Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochemical Research 30 (2005), 1037–1043.
203. Russo, E., Guy, G.W., A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Medical Hypotheses 66 (2006), 234–246.
204. 2 + levels. Journal of Neuroscience 29 (2009), 2053–2063.
205. Sacerdote, P., Martucci, C., Vaccani, A., Bariselli, F., Panerai, A.E., Colombo, A., et al. The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro. Journal of Neuroimmunology 159 (2005), 97–105.
206. Sagredo, O., Pazos, M.R., Satta, V., Ramos, J.A., Pertwee, R.G., Fernández-Ruiz, J., Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease. Journal of Neuroscience Research 89 (2011), 1509–1518.
207. Saijo, K., Glass, C.K., Microglial cell origin and phenotypes in health and disease. Nature Reviews Immunology 11 (2011), 775–787.
208. Salazar, M., Carracedo, A., Salanueva, I.J., Hernández-Tiedra, S., Egia, A., Lorente, M., et al. TRB3 links ER stress to autophagy in cannabinoid anti-tumoral action. Autophagy 5 (2009), 1048–1049.
209. Samara, E., Bialer, M., Harvey, D.J., Identification of glucose conjugates as major urinary metabolites of cannabidiol in the dog. Xenobiotica 20 (1990), 177–183.
210. Samara, E., Bialer, M., Harvey, D.J., Pharmacokinetics of urinary metabolites of cannabidiol in the dog. Biopharmaceutics & Drug Disposition 11 (1990), 785–795.
211. Samara, E., Bialer, M., Harvey, D.J., Metabolism of cannabidiol by the rat. European Journal of Drug Metabolism and Pharmacokinetics 16 (1991), 305–313.
212. Samara, E., Brown, N.K., Harvey, D.J., Microsomal metabolism of the 1″,1″-dimethylheptyl analogue of cannabidiol: Relative percentage of monohydroxy metabolites in four species. Drug Metabolism and Disposition 18 (1990), 548–549.
213. Sander, J.W., ILAE commission report. The epidemiology of the epilepsies: Future directions. International League against epilepsy. Epilepsia 38 (1997), 614–618.
214. +-induced toxicity in PC12 cells involves trkA receptors, upregulation of axonal and synaptic proteins, neuritogenesis, and might be relevant to Parkinson's disease. Toxicology In Vitro 30 (2015), 231–240.
215. Sastre, M., Klockgether, T., Heneka, M.T., Contribution of inflammatory processes to Alzheimer's disease: Molecular mechanisms. International Journal of Developmental Neuroscience 24 (2006), 167–176.
216. Schubart, C.D., Sommer, I.E.C., Fusar-Poli, P., de Witte, L., Kahn, R.S., Boks, M.P.M., Cannabidiol as a potential treatment for psychosis. European Neuropsychopharmacology, Vol. 24, 2014, 51–64.
217. Scott, K.A., Dalgleish, A.G., Liu, W.M., The combination of cannabidiol and Δ9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. Molecular Cancer Therapeutics 13 (2014), 2955–2967.
218. Scott, K.A., Dennis, J.L., Dalgleish, A.G., Liu, W.M., Inhibiting heat shock proteins can potentiate the cytotoxic effect of cannabidiol in human glioma cells. Anticancer Research 35 (2015), 5827–5837.
219. Scott, K.A., Shah, S., Dalgleish, A.G., Liu, W.M., Enhancing the activity of cannabidiol and other cannabinoids in vitro through modifications to drug combinations and treatment schedules. Anticancer Research 33 (2013), 4373–4380.
220. Scuderi, C., Steardo, L., Esposito, G., Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of beta amyloid expression in SHSY5YAPP + cells through PPARγ involvement. Phytotherapy Research 28 (2014), 1007–1013.
221. Sethi, K.D., Clinical aspects of Parkinson disease. Current Opinion in Neurology 15 (2002), 457–460.
222. Sharma, M., Hudson, J., Adomat, H., Guns, E., Cox, M., In vitro anticancer activity of plant-derived cannabidiol on prostate cancer cell lines. Pharmacology & Pharmacy 5 (2014), 806–820.
223. Shoval, G., Shbiro, L., Hershkovitz, L., Hazut, N., Zalsman, G., Mechoulam, R., et al. Prohedonic effect of cannabidiol in a rat model of depression. Neuropsychobiology 73 (2016), 123–129.
224. Showalter, V.M., Compton, D.R., Martin, B.R., Abood, M.E., Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands. Journal of Pharmacology and Experimental Therapeutics 278 (1996), 989–999.
225. Shrivastava, A., Kuzontkoski, P.M., Groopman, J.E., Prasad, A., Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Molecular Cancer Therapeutics 10 (2011), 1161–1172.
226. Singla, S., Sachdeva, R., Mehta, J.L., Cannabinoids and atherosclerotic coronary heart disease. Clinical Cardiology 35 (2012), 329–335.
227. Smiley, K.A., Karler, R., Turkanis, S.A., Effects of cannabinoids on the perfused rat heart. Research Communications in Chemical Pathology and Pharmacology 14 (1976), 659–675.
228. Soares Vde, P., Campos, A.C., Bortoli, V.C., Zangrossi, H. Jr., Guimarães, F.S., Zuardi, A.W., Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors. Behavioural Brain Research 213 (2010), 225–229.
229. Solinas, M., Massi, P., Cantelmo, A. R., Cattaneo, M. G., Cammarota, R., Bartolini, D. et al. (2012). Cannabidiol inhibits angiogenesis by multiple mechanisms. British Journal of Pharmacology, 167, 1218-1231.
230. Solinas, M., Massi, P., Cinquina, V., Valenti, M., Bolognini, D., Gariboldi, M., et al. Cannabidiol, a non-psychoactivecannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitargeteffect. PLoS One, 8, 2013, e76918.
231. Soroceanu, L., Murase, R., Limbad, C., Singer, E., Allison, J., Adrados, I., et al. Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target. Cancer Research 73 (2013), 1559–1569.
232. Sreevalsan, S., Joseph, S., Jutooru, I., Chadalapaka, G., Safe, S.H., Induction ofapoptosis by cannabinoids in prostate and colon cancer cells is phosphatasedependent. Anticancer Research 31 (2011), 3799–3807.
233. Stanley, C.P., Hind, W.H., O'Sullivan, S.E., Is the cardiovascular system a therapeutic target for cannabidiol?. British Journal of Clinical Pharmacology 75 (2013), 313–322.
234. Stanley, C.P., Hind, W.H., Tufarelli, C., O'Sullivan, S.E., Cannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB1 activation. Cardiovascular Research 107 (2015), 568–578.
235. Sturm, D., Gurevitz, S.L., Turner, A., Multiple sclerosis: A review of the disease and treatment options. Consultant Pharmacist 29 (2014), 469–479.
236. Su, E.N., Kelly, M.E., Cringle, S.J., Yu, D.Y., Role of endothelium in abnormal cannabidiol-induced vasoactivity in retinal arterioles. Investigative Ophthalmology & Visual Science 56 (2015), 4029–4037.
237. Takeda, S., Hirayama, A., Urata, S., Mano, N., Fukagawa, K., Imamura, M., et al. Cannabidiol-2′,6′-dimethyl ether as an effective protector of 15-lipoxygenase-mediated low-density lipoprotein oxidation in vitro. Biological and Pharmaceutical Bulletin 34 (2011), 1252–1256.
238. Tamagno, E., Bardini, P., Guglielmotto, M., Danni, O., Tabaton, M., The various aggregation states of β-amyloid 1–42 mediate different effects on oxidative stress, neurodegeneration, and BACE-1 expression. Free Radical Biology and Medicine 41 (2006), 202–212.
239. Thomas, A., Baillie, G.L., Phillips, A.M., Razdan, R.K., Ross, R.A., Pertwee, R.G., Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. British Journal of Pharmacology 150 (2007), 613–623.
240. Thomas, B.F., Gilliam, A.F., Burch, D.F., Roche, M.J., Seltzman, H.H., Comparative receptor binding analyses of cannabinoid agonists and antagonists. Journal of Pharmacology and Experimental Therapeutics 285 (1998), 285–292.
241. Torres, S., Lorente, M., Rodriguez-Fornes, F., Hernandez-Tiedra, S., Salazar, M., Garcìa-Taboada, E., et al. A combined preclinical therapy of cannabinoids and temozolomideagainst glioma. Molecular Cancer Therapeutics 10 (2011), 90–103.
242. Trapp, B.D., Nave, K.A., Multiple sclerosis: An immune or neurodegenerative disorder?. Annual Review of Neuroscience 31 (2008), 247–269.
243. Vaccani, A., Massi, P., Colombo, A., Rubino, T., Parolaro, D., Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. British Journal of Pharmacology 144 (2005), 1032–1036.
244. Valdepeñas, L., Martínez-Orgado, J.A., Benito, C., Millán, A., Tolón, R.M., Romero, J., Cannabidiol reduces lipopolysaccharide-induced vascular changes and inflammation in the mouse brain: An intravital microscopy study. Journal of Neuroinflammation, 8, 2011, 5.
245. Velasco, G., Sánchez, C., Guzmán, M., Towards the use of cannabinoids as antitumour agents. Nature Reviews Cancer 12 (2012), 436–444.
246. Velasco, G., Sánchez, C., Guzmán, M., Endocannabinoids and cancer. Handbook of Experimental Pharmacology 231 (2015), 449–472.
247. Vollner, L., Bieniek, D., Korte, F., Cannabidivarin, a new hashish constituent. Tetrahedron Letters 3 (1969), 145–147 (Hashish).
248. Walsh, S.K., Hepburn, C.Y., Kane, K.A., Wainwright, C.L., Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion. British Journal of Pharmacology 160 (2010), 1234–1242.
249. Walter, L., Franklin, A., Witting, A., Wade, C., Xie, Y., Kunos, G., et al. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. Journal of Neuroscience 23 (2003), 1398–1405.
250. Weiss, L., Zeira, M., Reich, S., Har-Noy, M., Mechoulam, R., Slavin, S., et al. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 39 (2006), 143–151.
251. Weiss, L., Zeira, M., Reich, S., Slavin, S., Raz, I., Mechoulam, R., et al. Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology 54 (2008), 244–249.
252. Westermann, D., Walther, T., Savvatis, K., Escher, F., Sobirey, M., Riad, A., et al. Gene deletion of the kinin receptor B1 attenuates cardiac inflammation and fibrosis during the development of experimental diabetic cardiomyopathy. Diabetes 58 (2009), 1373–1381.
253. Wheal, A.J., Cipriano, M., Fowler, C.J., Randall, M.D., O'Sullivan, S.E., Cannabidiol improves vasorelaxation in Zucker diabetic fatty rats through cyclooxygenase activation. Journal of Pharmacology and Experimental Therapeutics 351 (2014), 457–466.
254. Wirawan, E., Vande Walle, L., Kersse, K., Cornelis, S., Claerhout, S., Vanoverberghe, I., et al. Caspase-mediated cleavage of Beclin-1 inactivates Beclin-1-induced autophagy and enhances apoptosis by promoting the release of proapoptotic factors from mitochondria. Cell Death & Disease, 1, 2010, e18.
255. Wu, H.Y., Chu, R.M., Wang, C.C., Lee, C.Y., Lin, S.H., Jan, T.R., Cannabidiol-induced apoptosis in primary lymphocytes is associated with oxidative stress-dependent activation of caspase-8. Toxicology and Applied Pharmacology 226 (2008), 260–270.
256. Yamada, T., Ueda, T., Shibata, Y., Ikegami, Y., Saito, M., Ishida, Y., et al. TRPV2 activation induces apoptotic cell death in human T24 bladdercancer cells: a potential therapeutic target for bladder cancer. Urology 76:2 (2010), 509.e1–509.e7.
257. Zakrzeska, A., Schlicker, E., Baranowska, M., Kozłowska, H., Kwolek, G., Malinowska, B., A cannabinoid receptor, sensitive to O-1918, is involved in the delayed hypotension induced by anandamide in anaesthetized rats. British Journal of Pharmacology 160 (2010), 574–584.
258. Zanelati, T.V., Biojone, C., Moreira, F.A., Guimarães, F.S., Joca, S.R., Antidepressant-like effects of cannabidiol in mice: Possible involvement of 5-HT1A receptors. British Journal of Pharmacology 159 (2010), 122–128.
259. Zlebnik, N.E., Cheer, J.F., Beyond the CB1 receptor: Is cannabidiol the answer for disorders of motivation?. Annual Review of Neuroscience 39 (2016), 1–17.
260. Zuardi, A.W., Crippa, J.A., Hallak, J.E., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., et al. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Current Pharmaceutical Design 18 (2012), 5131–5140.
261. Zuardi, A.W., Crippa, J.A., Hallak, J.E., Moreira, F.A., Guimarães, F.S., Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Brazilian Journal of Medical and Biological Research 39 (2006), 421–429.
262. Zuardi, A.W., Crippa, J.A., Hallak, J.E., Pinto, J.P., Chagas, M.H., Rodrigues, G.G., et al. Cannabidiol for the treatement of psychosis in Parkinson's disease. Journal of Psychopharmacology 23 (2009), 979–983.
263. Zuardi, A.W., Morais, S.L., Guimarães, F.S., Mechoulam, R., Antipsychotic effect of cannabidiol. Journal of Clinical Psychiatry 56 (1995), 485–486.